patients trials potential drugs effective long symptom cognitive decline looking beta amyloid not option researchers believe disease markers example certain forms protein tau prove promising incorporated blood tests alzheimer beta amyloid levels start drop early disease process reach plateau tau markers later continue rise observation suggests amyloid tests work better early detection tau levels meaningful later stages disease verge decline symptomatic says oskar hansson neurologist lund university sweden year thijssen hansson published separate studies showing tau blood tests quanterix company billerica Massachusetts developed immunoassay detects amyloid tau conjunction neurological markers inflammatory proteins far tests not available outside research settings researchers